Taiwo BO - Search Results

1

Gibas KM, Kelly SG, Arribas JR, Cahn P, Orkin C, Daar ES, Sax PE, Taiwo BO. Gibas KM, et al. Among authors: taiwo bo. Lancet HIV. 2022 Dec;9(12):e868-e883. doi: 10.1016/S2352-3018(22)00249-1. Epub 2022 Oct 26. Lancet HIV. 2022. PMID: 36309038 Free PMC article. Review.

2

Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings.

Taiwo BO, Murphy R. Taiwo BO, et al. J Int Assoc Physicians AIDS Care (Chic). 2007 Sep;6(3):188-97. doi: 10.1177/1545109707300683. Epub 2007 May 1. J Int Assoc Physicians AIDS Care (Chic). 2007. PMID: 17473177

3

Understanding transmitted HIV resistance through the experience in the USA.

Taiwo B. Taiwo B. Int J Infect Dis. 2009 Sep;13(5):552-9. doi: 10.1016/j.ijid.2008.10.008. Epub 2009 Jan 10. Int J Infect Dis. 2009. PMID: 19136289 Free article. Review.

4

Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART.

Taiwo BO, Li X, Palella F, Jacobson LP, Margolick JB, Detels R, Rinaldo CR, Phair JP. Taiwo BO, et al. HIV Med. 2009 Nov;10(10):657-60. doi: 10.1111/j.1468-1293.2009.00739.x. Epub 2009 Jul 9. HIV Med. 2009. PMID: 19601997 Free PMC article.

5

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team. Sax PE, et al. N Engl J Med. 2009 Dec 3;361(23):2230-40. doi: 10.1056/NEJMoa0906768. Epub 2009 Dec 1. N Engl J Med. 2009. PMID: 19952143 Free PMC article. Clinical Trial.

6

Adherence to antiretroviral therapy: the more you look, the more you see.

Taiwo B. Taiwo B. Curr Opin HIV AIDS. 2009 Nov;4(6):488-92. doi: 10.1097/COH.0b013e3283311058. Curr Opin HIV AIDS. 2009. PMID: 20048715 Review.

7

Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.

Taiwo B, Chaplin B, Penugonda S, Meloni S, Akanmu S, Gashau W, Idoko J, Adewole I, Murphy R, Kanki P. Taiwo B, et al. Curr HIV Res. 2010 Apr;8(3):194-8. doi: 10.2174/157016210791111098. Curr HIV Res. 2010. PMID: 20163340

8

Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.

Taiwo B, Hicks C, Eron J. Taiwo B, et al. J Antimicrob Chemother. 2010 Jun;65(6):1100-7. doi: 10.1093/jac/dkq096. Epub 2010 Mar 25. J Antimicrob Chemother. 2010. PMID: 20348088 Review.

9

Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting.

Taiwo BO, Idoko JA, Welty LJ, Otoh I, Job G, Iyaji PG, Agbaji O, Agaba PA, Murphy RL. Taiwo BO, et al. J Acquir Immune Defic Syndr. 2010 May 1;54(1):85-92. doi: 10.1097/01.qai.0000371678.25873.1c. J Acquir Immune Defic Syndr. 2010. PMID: 20418724 Clinical Trial.

10

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C. Taiwo B, et al. Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Drugs. 2010. PMID: 20731472 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

147 results

Search Page